Advertisement

Topics

Novavax Company Profile

07:51 EDT 21st September 2018 | BioPortfolio

Novavax Inc. is a biotechnology company committed to leading the global fight against infectious diseases by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Our world-class scientific team is using virus-like particle (VLP) technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. Our team has created vaccines designed to protect against various circulating strains of avian influenza as well as seasonal flu. We have validated our approach in animals and are moving toward clinical testing. Our vision is a holistic approach to controlling the spread of disease. Using a unique portable manufacturing system that allows for rapid mass production, our long-term goal is to be able to rapidly deliver a customized vaccine in the midst of a pandemic. Novavax plans to apply its particle-based vaccine approach to other viral diseases beyond influenza.

Location

9920 Belward Campus Drive
Rockville
MD
20850
United States of America

Contact

Phone: (240) 268-2000
Email: ir@novavax.com


News Articles [42 Associated News Articles listed on BioPortfolio]

Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 9, 2018

GAITHERSBURG, Md., May 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S. ...

Novavax nets $54mm via FOPO

Infectious disease-focused Novavax Inc. netted $54mm through a follow-on public offering of 34.8mm common shares (including full exercise of the overallotment) at $1.65 each. The company will use some...

Novavax: Flu vaccine failings due to 'outdated' egg-based manufacturing

Egg adaptation is the biggest culprit in this yearâs poor flu vaccine efficacy says Novavax, a firm developing a product based on recombinant protein nanoparticles.

Novavax, Inc. Strategy, SWOT and Corporate Finance Report [Report Updated: 20062018] Prices from USD $175

Novavax, Inc. Strategy, SWOT and Corporate Finance ReportSummaryNovavax, Inc. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report cover...

Novavax to Host Conference Call and Webcast to Provide Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results

GAITHERSBURG, Md., March 07, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will provide a corporate update and report its fourth quarter and full year 2017 financial an...

Schwab Charles Investment Management Inc. Boosts Holdings in Novavax, Inc.

Schwab Charles Investment Management Inc. grew its stake in shares of Novavax, Inc. by 17.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund ow...

Novavax, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 17022018] Prices from USD $350

Novavax, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Novavax, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report include...

Novavax, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 26062018] Prices from USD $350

Novavax, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Novavax, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report include...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

E-Selectin Nasal Instillation to Prevent Secondary Stroke

This study will determine the maximum safe dose of the experimental drug E-selectin that can be given to stroke patients. E-selectin causes white blood cells called lymphocytes to change ...

Companies [2 Associated Companies listed on BioPortfolio]

Novavax, Inc.

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-par...

Novavax

Novavax Inc. is a biotechnology company committed to leading the global fight against infectious diseases by creating novel, highly potent vaccines that are safer and more effective than current preve...

More Information about "Novavax" on BioPortfolio

We have published hundreds of Novavax news stories on BioPortfolio along with dozens of Novavax Clinical Trials and PubMed Articles about Novavax for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novavax Companies in our database. You can also find out about relevant Novavax Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Corporate Database Quicklinks



Searches Linking to this Company Record